Manual práctico de Trombosis y Hemostasia de la SETH

— 9 1 — 4 . I n h i b i d o r e s a d q u i r i d o s d e l a c o a g u l a c i ó n la hemoglobina al diagnóstico y la respuesta al trata- miento erradicador. – Optimizar tratamiento hemostático: previene morbi- mortalidad precoz. – Optimizar tratamiento erradicador: previene morbi- mortalidad a medio y largo plazo. – El tratamiento erradicador debe iniciarse tan pronto como se realice el diagnóstico y debe ser individualiza- do de acuerdo con las características del paciente BIBLIOGRAFÍA 1. Hunth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diag- nosis and treatment of pacientes with acquired hemophilia A. Haematologica 2009;94:566-75. 2. Knoelb P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012;10:622-31. 3. Kruse-Jarres R,Kempton CL,Baudo F,Collins PW,Knoebl P,Leissing- er CA, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol 2017;92(7):695-705. 4. Mingot-Castellano ME, Núñez R, Rodríguez-Martorell FJ. Ac- quired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. Med Clin (Barc); 2017;148(7):314-22. 5. Franchini M, Vaglio S, Marano G, Mengoli C, Gentili S, Pupella S, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology 2017;22(9):514-20. 6. André S, Meslier Y, Dimitrov J, Repessé Y, Kaveri S, Lacroix-Des- mazes S, et al.A CellularViewpoint of Anti-FVIII Immune Respon- se in Hemophilia A. Clinic Rev Allerg Immunol 2009;37:105-13. 7. Wootla B, Desirazu N, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri S. Varied Immune Response to FVIII: Presence of Pro- teolytic Antibodies Directed to Factor VIII in Different Human Pathologies. Clinic Rev Allerg Immunol 2009;37:97-104. 8. Lavigne-Lissalde G, Rothschild C, Pouplard C, Lapalud P, Gruel Y, Schved J, et al. Characteristics, Mechanisms of Action, and Epitope Mapping of Anti-factor VIII Antibodies. Clinic Rev Allerg Immunol 2009;37:67-79. 9. Nemes L, Tengborn L, Collins PW, Baudo F, Huth-Kuehne A, Knoebl P, et al. Acquired Haemophilia and pregnancy/postpar- tum- a Report from an European Acquired Registry. Blood 2010;116:717. 10. Collins PW, Chalmers E, Hart D, Jennings I, Liesner R, Rangarajan S, et all. On behalf of United Kingdom Haemophilia Centre Doc- tors’ Organization. Diagnosis and management of acquired coa- gulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013;162(6):758-73. 11. Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Lászlós N et al. Management of bleeding in acquired hemophilia A: results from the European Acquired haemophilia (EACH2) Registry. Blood 2012;120:39-46. 12. Dunkley SM, Yang K. The use of combination FEIBA and rFVIIa bypassing therapy with TEG profiling in uncontrollable bleed- ing associated with acquired haemophilia A. Haemophilia 2009;15:828-30. 13. Al-Mondhiry HAB, Ma A, Kessler CM, Fisher M, Gut RZ, Coo- per DL. US experience with recombinant factor VIIa (rFVIIa) for surgery in acquired hemophilia (AH): analysis from the Hemo- stasis and Thrombosis Research Society (HTRS) registry. Blood 2012;120:3372. 14. Takedani H, Shima M, Horikoshi Y, Koyama T, Fukutake K, Kuwahara M, et al. Ten-year experience of recombinant activat- ed factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia 2015;21:374-9. 15. Kruse-Jarres R,St-Louis J,Greist A,ShapiroA,Smith H,Chowdary P, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired hae- mophilia A. Haemophilia 2015;21:162-70. 16. Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Roca CA, Hirnyk MI, Jiménez-Yuste V, et al. Spanish consen- sus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. Eur J Haematol 2016;96(5):461-74. 17. Zanon E, Milan M, Gamba G,Ambaglio C, Saggiorato G, Spiezia L, et al. Activated prothrombin complex concentrate (FEIBA ® ) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.Thromb Res 2015;136:1299-302. 18. Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014;124(20):3165-71. 19. Tiede A, Scharf RE, Dobblestein C,Werwitzke S. Management of acquired haemophilia A. Häemostaseologie 2015;35(4):311-8. 20. Tiede A, Klamroth R, Scharf RE, Holstein K, Huth-Kühne A, Gott- stein S, et al. Prognostic factors for remission of and survival in ac- quired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015;125:1091-7. 21. Delgado J, Jiménez-Yuste V, Hernández-Navarro F,Villar A. Acqui- red haemophilia: review and meta analysis focused on therapy and prognostic factors. Br J Haematol 2003;121(1):21-35. 22. Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis 2009;20:517-23. 23. Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pelegrini F, et al. Immunosuppression for acquired haemophilia A: results from de European Acquired Haemophilia Registry (EACH2). Blood 2012;120(1):47-55.